PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in <i>SMARCA4</i> -Mutated Cancers

PRT3789 selectively degrades SMARCA2 and demonstrates activity in SMARCA4-deficient cancers while sparing wild-type models, validating paralog synthetic lethality, and supporting clinical development in SMARCA4-mutated patients, a population with high unmet need.